Vorinostat in Treating Patients With Metastatic or Unresectable Melanoma

NCT00121225 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

32

Enrollment

NIH

Sponsor class

Conditions

Ciliary Body and Choroid Melanoma, Medium/Large Size
Extraocular Extension Melanoma
Iris Melanoma
Uveal Melanoma
Recurrent Intraocular Melanoma
Recurrent Melanoma
Stage IV Melanoma

Interventions

DRUG: vorinostat

Sponsor

National Cancer Institute (NCI)